Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer (VIRAGE2)

24 juli 2026 bijgewerkt door: Theriva Biologics SL

A Phase IIa, Single-arm, Single-center, Open Label, Proof-of-concept Trial Evaluating Increased Frequency Dosing of VCN-01 (Zabilugene Almadenorepvec) in Combination With Nab-Paclitaxel/Gemcitabine (GnP) in Patients With Newly-Diagnosed Metastatic Pancreatic Cancer

The goal of this clinical trial is to learn if the new administration regimen of VCN-01, given together with the standard chemotherapy drugs gemcitabine and nab-paclitaxel (GnP), is safe and well tolerated. The behaviour of VCN-01 in the organism will be assessed, together with the possible benefits of this administration regimen. This study includes adults with newly diagnosed pancreatic ductal adenocarcinoma (PDAC) that has spread to other parts of the body (stage IV) and who have not received prior treatment for pancreatic cancer.

Participants will receive three planned doses of VCN-01, given once every 56 days. Each dose of VCN-01 is followed one week later by two cycles of standard chemotherapy with gemcitabine and nab-paclitaxel. Participants will be monitored throughout the study for safety and side effects.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

6

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Madrid
      • Madrid, Madrid, Spanje, 28041
        • Werving
        • Hospital 12 de Octubre
        • Contact:
          • Victoria López, Study Coordinator
          • Telefoonnummer: 452750 +34 91 390 8950
          • E-mail: rcarbonero@gmail.com
        • Hoofdonderzoeker:
          • Rocío García Carbonero, Dr

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Written informed consent obtained prior to initiating any trial-specific procedures or assessments.
  • Male or female patients aged 18 years or over.
  • Patients with histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic (stage IV) at diagnosis and who have not received any treatment for their pancreatic cancer.
  • Patients must be able to receive their first dose of VCN-01 ≤6 weeks after their metastatic pancreatic cancer diagnosis.
  • Patients must have at least one measurable tumor lesion that can be imaged for assessments according to RECIST 1.1.
  • ECOG performance status of 0 or 1 at enrollment.
  • Must be willing to comply with the trial intervention, including prophylactic medications, and procedures.
  • Adequate baseline organ function (hematologic, liver, renal) within the 7 days prior to enrollment:

Hematology:

  • Leukocytes ≥3.0x103 mcL
  • Absolute neutrophil count ≥1.5x10⁹/L
  • Hemoglobin ≥9 g/dL
  • Platelets ≥100x10⁹/L

Coagulation:

  • Prothrombin time or international normalized ratio ≤1x upper limit of normal (ULN)
  • Activated partial thromboplastin time ≤1.2xULN

Hepatic:

  • Total bilirubin ≤1.5xULN
  • ALT and AST ≤2.5xULN (<5xULN is acceptable if liver metastases are present)

Renal:

  • Serum creatinine ≤1.5xULN; or,
  • If serum creatinine >1.5xULN, an estimated creatinine clearance >50 mL/min using the Cockcroft and Gault formula

Nutritional:

• Serum Albumin ≥30 g/L

- Adequate left ventricular ejection fraction (LVEF) ≥ 50% measured by ECHO or MUGA and QT interval corrected by Fridericia (QTcF) assessment ≤ 450 ms for men or ≤ 470 ms for women.

Exclusion Criteria:

  • Unwillingness to complete the trial procedures for geographic, psychiatric, or social reasons.
  • Patient has previously received treatment for their metastatic pancreatic cancer with surgery, radiotherapy, chemotherapy or investigational therapy; except that:
  • Palliative radiotherapy for pain is permitted;
  • Placement of a biliary stent/tube is permitted.
  • Patients who, in the opinion of the investigator, have symptoms or signs suggesting clinically unacceptable deterioration during the Screening Period.
  • Active infection or other serious illness or autoimmune disease at the moment of enrollment. Active infection includes:

    • Tuberculosis (TB; clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice.

  • Patients with past or resolved TB are eligible to participate.

    • Hepatitis B Virus (HBV; positive HBV surface antigen [HBsAg] result).

  • HBV carriers (patients positive for HBsAg without an active infection) are not eligible to participate;
  • Patients requiring antiviral medicines for HBV prophylaxis or treatment are not eligible to participate;
  • Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible to participate provided that blood HBV DNA is negative at enrollment.

    • Hepatitis C Virus (HCV; positive HCV Ribonucleic acid [RNA]).

  • Patients requiring antiviral medicines for HCV prophylaxis or treatment are not eligible to participate;
  • Patients positive for HCV antibody are eligible to participate (only if polymerase chain reaction is negative for HCV RNA).

    • Human immunodeficiency virus (positive HIV 1/2 antibodies)

Active infection or other serious illness or autoimmune disease at the moment of enrollment. Active infection includes:

  • Tuberculosis (TB; clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice.

    - Patients with past or resolved TB are eligible to participate.

  • Hepatitis B Virus (HBV; positive HBV surface antigen [HBsAg] result).

    • HBV carriers (patients positive for HBsAg without an active infection) are not eligible to participate;
    • Patients requiring antiviral medicines for HBV prophylaxis or treatment are not eligible to participate;
    • Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible to participate provided that blood HBV DNA is negative at enrollment.
  • Hepatitis C Virus (HCV; positive HCV Ribonucleic acid [RNA]).

    • Patients requiring antiviral medicines for HCV prophylaxis or treatment are not eligible to participate;
    • Patients positive for HCV antibody are eligible to participate (only if polymerase chain reaction is negative for HCV RNA).
  • Human immunodeficiency virus (positive HIV 1/2 antibodies)

    • Known chronic liver disease (e.g. liver cirrhosis, liver fibrosis, chronic hepatitis); except that:
    • Patients with fatty liver disease are eligible to participate if their liver transaminases meet inclusion criterion 8.
    • Concurrent malignant hematologic or solid disease; except that:
    • Patients with a prior history of cancer are eligible to participate if they are in complete remission from their prior cancer for at least 3 years.
    • Patients with Li Fraumeni syndrome or with previously known retinoblastoma protein pathway germline deficiency.
    • Patients with untreated brain metastases and/or leptomeningeal carcinomatosis with progressive symptoms despite corticosteroid coverage; except that:
    • Patients with brain metastases with stable symptoms are eligible to participate.
    • Patients with previous pneumonitis or interstitial lung disease.
    • Patients with pre-existing sensory neuropathy >G1
    • Clinical evidence of deep vein thrombosis, pulmonary embolism or arterial thromboembolic event during the Screening Period.
    • Patients with superficial vein thrombosis are eligible to participate.
    • Patients with uncontrolled coagulopathy.
    • Any other condition, disease, metabolic dysfunction (e.g., uncontrolled diabetes mellitus), active or uncontrolled infection/inflammation, physical examination finding, mental state or clinical laboratory finding that would contraindicate participation in the clinical trial due to concerns over safety or potential non-compliance with clinical trial procedures.
    • A female patient, who is pregnant or lactating.
    • Female patients of reproductive potential must agree to use a highly effective method of birth control. Male patients must agree to use condoms.
    • Treatment with live attenuated vaccines in the last 3 weeks before the administration of the IMP.
    • Treatment with an adenovirus type-5 (Ad5)-based COVID-vaccine in the last 12 weeks before the administration of the IMP.
    • Treatment with another investigational agent within five of that investigational agent's half-lives prior to the administration of the IMP.
    • Chronic immunosuppressive therapy; except that:
    • Inhaled corticosteroids are permitted;
    • Oral or IV corticosteroids with a dose lower than 10 mg prednisone or equivalent/day are permitted;
    • Dexamethasone up to a maximum dose of 1 mg/day is permitted.
    • Known allergy or hypersensitivity to any of the trial-specific interventions or any of their excipients.
    • Subjects, for whom first line treatment options other than the combination nab-paclitaxel/gemcitabine are recommended by the investigator.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: High dose
The initial dosing regimen for this study comprises three "macrocycles", each of which comprises one dose of VCN-01 followed one week later by 2 cycles of GnP according to standard of care
The initial dosing regimen for this study comprises up to three "macrocycles", each of which comprises one dose of VCN-01 followed one week later by 2 cycles of GnP according to standard of care (SoC)
IV nab-paclitaxel (starting dose 125 mg/m²) followed by IV gemcitabine (starting dose 1,000 mg/m²) according to SoC clinical practice (GnP SoC). Dose modifications and interruptions permitted per prescribing information/SmPC.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Pharmacokinetics (PK) of VCN-01
Tijdsspanne: From enrollment up to 30 days from the last dose of study intervention
VCN-01 concentration in blood at predefined time points.
From enrollment up to 30 days from the last dose of study intervention
Incidence of Treatment-Emergent Adverse Events
Tijdsspanne: From enrolment up to 30-days from the last dose of study intervention
Frequency and proportion of participants experiencing AEs/SAEs; descriptive statistics for laboratory values.
From enrolment up to 30-days from the last dose of study intervention

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

3 augustus 2026

Primaire voltooiing (Geschat)

1 augustus 2027

Studie voltooiing (Geschat)

1 december 2027

Studieregistratiedata

Eerst ingediend

8 juli 2026

Eerst ingediend dat voldeed aan de QC-criteria

8 juli 2026

Eerst geplaatst (Werkelijk)

14 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

27 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

24 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • P-VCNA-004

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .